Business Model

Lipigon creates value for patients and shareholders by developing innovative drugs for treatingof lipid-related diseases. This development process can occur either independently or in collaboration with other pharmaceutical companies.

For indications that require a large sales and marketing organization, Lipigon intends to enter into commercial agreements with one or more major pharmaceutical companies. This approach ensures an optimal route to market and sets the stage for commercial success. These commercial agreements are structured to include an upfront payment upon contract signing, ongoing payments upon achieving significant developmental milestones, and royalty earnings upon the drugs' sale.

For the commercialization of specialized medications, Lipigon retains the flexibility to assume marketing responsibilities in specific regions where the prescriber base is limited.